Founder commentary
India’s pharma quality reset will be won after the inspector leaves
In 
ET Pharma, Varun Sharma argues that pharmaceutical quality depends on what an organisation can prove after inspection: whether failures recur, remediation holds and accountable people can trace each decision.
Founder commentary · ET Pharma
Publication record / 01NEUVIOR summary
Quality must survive normal operations.
An inspection can expose a failure and trigger enforcement. It cannot, on its own, show whether the correction will still hold on the next shift, during the next deviation or when commercial pressure returns.
Varun Sharma’s argument is that durable quality depends on evidence of recurrence, accountable decisions and learning that changes how an organisation allocates attention, people and capital.
Measure what returns, not only what closes.
Closing an action is an administrative event. The harder test is whether the same failure appears again, whether overdue work escalates, whether effectiveness checks use independent evidence and whether repeat deviations travel across products, lines or sites.
- Repeat findings and recurrence after closure
- Time to verified remediation
- Unresolved critical risks
- Management decisions that changed resources, maintenance, suppliers or production
Connect signals without claiming more than they prove.
Government figures published on 24 March 2026 reported risk based inspections at more than 960 premises since December 2022 and more than 860 regulatory actions. They also reported 116,323 samples tested during 2024 to 2025, of which 3,104 were not of standard quality and 245 were spurious or adulterated.
These are national totals. They cannot diagnose the quality system at any individual site. Their value is in helping regulators select risk, identify patterns and decide where verification deserves priority.
Keep accountable humans in control of automation.
The April 2026 IndiaAI and CDSCO hackathon invited teams to work on anonymisation, document summarisation, missing field detection, severity classification, version comparison and formal reporting from handwritten notes. It was a development challenge, not proof of a deployed regulatory system.
Automation may structure evidence and expose gaps. It should not own legal judgement. Each summary should remain traceable to source material. Each severity change should identify its approver. Each override should retain a reason.
Move recurring quality risk into board decisions.
A recurring risk ledger can connect quality evidence with capital expenditure, supplier qualification, staffing, maintenance and production incentives. This turns quality from a departmental reporting exercise into an operating responsibility shared by senior leadership.
Smaller manufacturers still need a demanding route. Common definitions, a minimum evidence standard, phased technical assistance and firm escalation for repeat failure can improve capability without rewarding paperwork for its own sake.
What this means for NEUVIOR.
The commentary reflects a governance principle in NEUVIOR’s public thinking. Technology may organise evidence and reveal gaps, but it must not conceal who decides, what remains uncertain or why an override occurred.
The article does not present PHARMORIS as the answer. It does not report a NEUVIOR deployment, a customer relationship, regulatory approval, clinical efficacy or demonstrated healthcare outcomes.
“Only what happens afterwards can change it.”
Varun Sharma,
Primary source context
- Government quality measures and sampling data
Ministry of Health and Family Welfare release dated 24 March 2026.
- IndiaAI and CDSCO hackathon announcement
Ministry of Electronics and Information Technology release dated 2 April 2026.
- Revised Schedule M notification
Official notification issued by the Ministry of Health and Family Welfare.
An automated packaging line makes the physical production setting visible. This external stock photograph is illustrative and separate from the national inspection evidence discussed in the article.
imagesourcecurated · Medicine Production with Robotic Equipment in FactoryEnvato Elements commercial licence
Source and image notes
Full frame retained; EXIF orientation honoured, proportionally resized and encoded as WebP. No crop, recolouring, compositing or generative changes.
Quality and manufacturing leaders
Does the correction survive the next ordinary shift?
Closing an inspection action and changing the conditions that caused a failure are different achievements. Explore the evidence that connects a corrective action with subsequent operations. The visual supports the article’s quality argument while keeping administrative closure, recurrence and independent effectiveness review visibly separate.
Editorial decision model, not measured NEUVIOR results. Sources identify the published context; selected lenses do not establish product performance, customer adoption or institutional endorsement.
A closure record needs an effectiveness question.
Quality teams can use the article to distinguish completion from evidence that a correction remains effective. The appropriate comparison depends on the failure, process and risk. A local review should specify its definitions and evidence before making a claim about lasting improvement.
What evidence would show the correction did not hold?
Recurring risk should change a resource decision.
A board needs to understand whether recurring weaknesses require attention, people or capital. It should see the basis for that judgement, including uncertainty and differences between sites or processes. An attractive dashboard of closed actions cannot answer the operating question on its own.
Which decision would a credible recurrence finding change?
The action closed
A completed action records that a defined task has reached its administrative end. Its documentation matters, but it does not independently establish that the original failure cannot recur. Begin by identifying exactly what was changed and which condition the action was intended to address.
- Return to operation
- Different evidence
The specific action, responsible owner and documented change.
A useful next stepAsk what the closure record actually establishes.
Durable quality is examined through operating evidence and accountable effectiveness review, beyond an action’s closure.
A NEUVIOR conversation
Bring a question worth pursuing.
A useful discussion begins with the decision you face, the evidence available and what a clearer answer would change.
Related newsroom records
Continue through the latest record.
AI and Accountability: When Does a Suggestion Become a Decision?
AI Ethics Now | University of Warwick IATL · 23 August 2026Approval is not access: Pilots' real test is implementation
Pharmaphorum · 18 August 2026Five questions to test whether an AI stack is truly under your control
TechRadar Pro · 11 August 2026
